Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

NCT05200936 ↗

Phase 2 Completed 53 enrolled Definium Therapeutics US, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled

Timeline

Start: 2021-12-17
Primary completion: 2023-11-06
Completion: 2023-12-04

Outcome

Missed primary endpoint

paper The placebo group presented a mean AISRS improvement of -8.9 points (95% CI, -12.0 to -5.8), with no difference between groups. PMID 40105807 ↗

paper it was not more efficacious than placebo in reducing ADHD symptoms. PMID 40105807 ↗

Publications

Haijen-Bongers ECHM, Hurks PPM, Schepers J, Vizeli P, Santos de Jesus J, Mueller L, Schmid Y, Liechti ME, Kuypers KPC. Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: a randomized placebo-controlled study. Psychopharmacology (Berl). 2026 Jun 20. doi: 10.1007/s00213-026-07107-7. Online ahead of print.
Mueller L, Santos de Jesus J, Schmid Y, Muller F, Becker A, Klaiber A, Straumann I, Luethi D, Haijen ECHM, Hurks PPM, Kuypers KPC, Liechti ME. Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Jun 1;82(6):555-562. doi: 10.1001/jamapsychiatry.2025.0044.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MM120	Unknown	20 ug	Oral